Active pharmaceutical ingredient maker Morepen Laboratories has received approval for anti-allergy API Loratadine from the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA).
China represents a vast growth opportunity and the approval will enable the company to meet a rising demand for high-quality antihistamine and anti-allergy APIs, Director – Sales and Marketing Kushal Suri said on Tuesday. The company’s shares ended 3.16% higher at ₹49.36 apiece on the BSE.
The approval will pave the way to capture a significant share of the Chinese market and help consolidate Morepen’s position as a dominant global manufacturer of Loratadine. A second-generation antihistamine and anti-allergy drug, Loratadine is used to treat allergic symptoms such as hay fever and chronic urticaria.
Morepen commands an over 80% market share in the U.S. generics market for Loratadine. It has been exporting to the US market for over 25 years and its API exports alone are valued at ₹650 crore, the company said in a release.
Published – April 01, 2025 09:17 pm IST
